Patrick Lee Green, PhD

Patrick Lee Green, PhD

Academic Title: Professor and Associate Dean

Research Program: Leukemia and Hematologic Malignancies

Contact Information
  • About Me

    I am a professor and associate dean for research and graduate studies in the College of Veterinary Medicine at The Ohio State University, where I also direct the Center for Retrovirus Research. I am the associate director for basic sciences at the OSUCCC – James and a member of the Leukemia and Hematologic Malignancies Program.

    My research focuses on understanding the molecular basis of T-lymphocyte transformation, as well as the induction of leukemia/lymphoma and neurological diseases by the human T-cell leukemia viruses (HTLVs). My lab investigates viral and cellular regulators of HTLV gene expression/replication, cellular transformation and virus survival or persistence in infected hosts.

    Recent work has revealed the importance of a viral gene, termed Hbz, in the maintenance and proliferation of HTLV-1 infected cells. In fact, Hbz is the only viral gene consistently expressed in HTLV-1 associated adult T cell leukemia/lymphoma. Hbz and the cellular pathways it impacts will be important targets for treatment and prevention of HTLV-1-associated diseases.

    I have authored or co-authored many articles in well-regarded publications, including Viruses, Journal of Virology, Blood, Retroviology and Cancer Cell.

  • Research Interests

    • Human T-Lymphotropic Virus 1
    • Leukemia-Lymphoma, Adult T-Cell
  • Academic Office & Contact Information

    Academic Office:

    Veterinary Medicine Academic
    1900 Coffey Rd
    Columbus, Ohio 43210-1006

  • Publications

    March 26, 2024

    Vulnerability to APOBEC3G linked to the pathogenicity of deltaretroviruses.

    Shichijo T, Yasunaga JI, Sato K, Nosaka K, Toyoda K, Watanabe M, Zhang W, Koyanagi Y, Murphy EL, Bruhn RL, Koh KR, Akari H, Ikeda T, Harris RS, Green PL, Matsuoka M

    Proc Natl Acad Sci U S A

    January 9, 2024

    An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.

    Tu JJ, King E, Maksimova V, Smith S, Macias R, Cheng X, Vegesna T, Yu L, Ratner L, Green PL, Niewiesk S, Richner JM, Panfil AR

    J Virol

    June 1, 2023

    HTLV-1 Hbz protein, but not hbz mRNA secondary structure, is critical for viral persistence and disease development.

    Maksimova V, Wilkie T, Smith S, Phelps C, Melvin C, Yu L, Niewiesk S, Green PL, Panfil AR

    PLoS Pathog

    January 14, 2022

    Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T cell leukemia/lymphoma.

    Daenthanasanmak A, Bamford RN, Yoshioka M, Yang SM, Homan PJ, Karim B, Bryant BR, Petrus MN, Thomas C, Green PL, Miljkovic MD, Conlon KC, Waldmann TA

    Blood Adv

    November 24, 2021

    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.

    Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, Bryant BR, Petrus MN, Bachy E, Huang DW, Yang Y, Green PL, Hasegawa H, Maeda M, Goto H, Endo T, Yokota T, Hatanaka KC, Hatanaka Y, Tanaka S, Matsuno Y, Yang Y, Hashino S, Teshima T, Waldmann TA, Staudt LM, Nakagawa M

    Blood

    May 21, 2021

    Epigenomic regulation of human T-cell leukemia virus by chromatin-insulator CTCF.

    Cheng X, Joseph A, Castro V, Chen-Liaw A, Skidmore Z, Payton JE, Ratner L, Edwards JR, Ueno T, Fujisawa JI, Rauch DA, Challen GA, Martinez MP, Green P, Griffith M

    PLoS Pathog